Sellas Cancer Vaccine Beats Phase 3, Slashing Death Risk 41%

Sellas' galinpepimut-S hit its Phase 3 goal in advanced AML, delivering 24-month median survival and a 41% cut in death risk versus standard care.

@sharedot

Sellas Cancer Vaccine Beats Phase 3, Slashing Death Risk 41%

By @sharedot · · 6 pages

  • Stock Market
  • Biotech
  • Sellas Life Sciences
  • Clinical Trials

Sellas' galinpepimut-S hit its Phase 3 goal in advanced AML, delivering 24-month median survival and a 41% cut in death risk versus standard care.

A surprise win in acute myeloid leukemia

Sellas Life Sciences reported Tuesday that its lead candidate, the peptide cancer vaccine galinpepimut-S, met the primary endpoint of its Phase 3 trial in advanced acute myeloid leukemia.

The WT1-targeted vaccine delivered a median overall survival of 24 months versus less than 15 months for best available therapy, a more than nine-month improvement, and cut the risk of death by 41%.

Sellas plans to begin an accelerated filing with the FDA for the treatment, which is licensed from Memorial Sloan Kettering Cancer Center and holds an agency orphan designation granted in 2023.

Why the market and skeptics did not see this coming

The result upended expectations in a niche clinical-stage biotech.

STAT columnist Adam Feuerstein had published a column in September predicting galinpepimut would fail to prolong survival in the Phase 3 study, and he opened his Tuesday coverage by conceding, 'It looks like I was wrong about Sellas.'

STAT called the outcome 'the unexpected result' and good news for AML patients.

Inside the trial that finally read out

The study enrolled 126 patients split between GPS alone and treatments including chemotherapy and AbbVie and Roche's Venclexta, according to Fierce Biotech.

The final analysis required 80 patient deaths; Sellas said last year it was taking longer than anticipated to reach that threshold, and the count was not complete until late October 2026. Safety and tolerability were normal.

What comes next for Sellas

Sellas CEO Angelos Stergiou, M.D., called the magnitude of the survival benefit 'a defining milestone for Sellas' and said it provides Phase 3 validation of the company's WT1-targeted immunotherapeutic technology, positioning GPS as a potential 'paradigm-shifting option' for this high-risk population, per the company's release cited by Fierce Biotech.

Beyond AML, GPS is in mid-stage testing as a mesothelioma monotherapy and in combinations with Bristol Myers Squibb's Opdivo and Merck's Keytruda. Sellas also expects to present response and survival data next month for its small molecule SLS009 at the American Society of Hematology annual meeting.

Sources

  1. fiercebiotech.com › Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
  2. statnews.com › Sellas' experimental blood cancer immunotherapy reduced risk of death in clinical trial

More on Stock Market